Jefferies raised the firm’s price target on HCA Healthcare (HCA) to $525 from $485 and keeps a Buy rating on the shares after “a good Q3, with a solid EBITDA beat.” The magnitude of the Q3 beat highlighted how significant the upside could be from other upcoming state-directed payments approvals and made investors overlook the impasse in Congress over health insurance exchange subsidies, the analyst contends.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on HCA:
- HCA Healthcare Announces Senior Notes Offering
- HCA Healthcare price target raised to $495 from $460 at Truist
- HCA Healthcare price target raised to $500 from $450 at Stephens
- HCA Healthcare price target raised to $482 from $449 at RBC Capital
- HCA Healthcare: Hold Rating Amid Policy Uncertainties and Volume Growth Concerns